LEXX News and Press, Lexaria Bioscience Corp.

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic that the studies will yield positive results, not just in the potentia...

Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2 The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration ...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to oversee execution of the company’s 12-week chronic study GLP-1-H24-4. The study will evaluate various DehydraTECH...

Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives KELOWNA, BC / ACCESSWIRE / June 18, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has now hired a contract research org...

(TheNewswire) Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives Kelowna, British Columbia – June 18, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a glo...

Lexaria, a global innovator in drug delivery platforms, recently announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study The study, a randomized, crossover investigation, will evaluate a dual-action glucagon-like peptide 1 (“GLP-1&#x...

2024-06-14 07:15:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Let me be clear: investing in biotech stocks isn’t for everyone. Investing in smaller biotech companies requires research, patience, and risk tolerance. Investing in A-rated biotech ...

Lexaria recently received two new patents granted in the U.S. in its patent families #21 and #24 The new patents complement the company’s efforts in investigating the capabilities of DehydraTECH-CBD to lower blood pressure in humans with hypertension and mitigate epileptic seizures in ro...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is reporting that the second round of dosing for all nine study participants in the second arm of its human pilot study #2 has been completed. The company anticipates completion of the final arm of the study...

(TheNewswire) Second study arm dosing is now complete. Kelowna, British Columbia – June 5, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug d...